Affymetrix Blames 12 Percent Q2 Sales Drop on Weak European Performance, Sales Reorganization

Despite its disappointing Q2 performance, the firm's management assuaged investors last week that all anticipated instrument orders remain in its pipeline, and that any "disruption" associated with sales restructuring has passed.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.